Adage Capital reports 1.54M Karyopharm (KPTI) shares, a 6.78% stake
Rhea-AI Filing Summary
Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports beneficial ownership of 1,536,736 shares of Karyopharm Therapeutics Inc. common stock, including 15,414 shares issuable upon exercise of warrants, held through Adage Capital Partners, L.P.
This position represents 6.78% of Karyopharm’s common stock, based on 22,662,943 shares outstanding as of May 7, 2026. All voting and dispositive authority over these shares is reported as shared, with no sole voting or dispositive power listed for any reporting person.
Positive
- None.
Negative
- None.
Key Figures
Beneficially owned shares: 1,536,736 shares
Ownership percentage: 6.78%
Shares outstanding: 22,662,943 shares
+3 more
6 metrics
Beneficially owned shares
1,536,736 shares
Shares of Karyopharm common stock beneficially owned by the reporting persons
Ownership percentage
6.78%
Portion of Karyopharm common stock class beneficially owned
Shares outstanding
22,662,943 shares
Karyopharm common stock outstanding as of May 7, 2026
Warrant shares included
15,414 shares
Common shares issuable upon exercise of warrants held by Adage Capital Partners, L.P.
Sole voting power
0 shares
Shares over which reporting persons have sole voting power
Shared voting power
1,536,736 shares
Shares over which reporting persons have shared voting power
Key Terms
beneficial ownership, shared voting power, shared dispositive power, warrants, +1 more
5 terms
beneficial ownership financial
"The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
warrants financial
"Includes 15,414 shares of Common Stock issuable upon exercise of warrants"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
Schedule 13G regulatory
"The percentage set forth in this is calculated based upon an aggregate of 22,662,943 shares"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What percentage of Karyopharm Therapeutics (KPTI) does Adage Capital report owning?
Adage Capital and its affiliates report beneficial ownership of 6.78% of Karyopharm Therapeutics’ common stock. This percentage is based on 22,662,943 shares outstanding as of May 7, 2026, and includes shares issuable upon exercise of warrants.
Who are the reporting persons in the KPTI Schedule 13G/A for Adage Capital?
The reporting persons are Adage Capital Management, L.P., and individuals Robert Atchinson and Phillip Gross. They report beneficial ownership of Karyopharm shares held through Adage Capital Partners, L.P., including shares issuable upon exercise of warrants.